• Non ci sono risultati.

Expression Studies of Recombinant FVIII Proteins Exhibiting Mutations in the B-Domain

N/A
N/A
Protected

Academic year: 2022

Condividi "Expression Studies of Recombinant FVIII Proteins Exhibiting Mutations in the B-Domain"

Copied!
4
0
0

Testo completo

(1)

Expression Studies of Recombinant FVIII Proteins Exhibiting Mutations in the B-Domain

K. Klempau, H. Singer, C. Klein, H.-H. Brackmann, P. Hanfland, T. Tonn, R. Schwaab and J. Oldenburg

Introduction

The phenotype of hemophilia A is due to the deficiency or absence of coagulation fac- tor VIII (FVIII) caused by a great number of heterogeneous mutations within the large FVIII gene, including various point mutations, inversions and deletions or in- sertions. Missense mutations have been of special interest because they point to func- tional important regions of the FVIII molecule. Notably, missense mutations are sig- nificantly underrepresented in the middle part of the B-domain, indicating that this part of the FVIII molecule may be less important for its function. Furthermore, the successful treatment with a B-domain deleted recombinant FVIII-concentrate, shows that the B-domain might be dispensable for a functional FVIII protein. However, in some hemophilia A patients a missense mutation was the only sequence variation found within the FVIII gene, even by sequencing the complete coding region (Fig. 1).

Materials and Methods

Missense mutations within the B-domain were identifying in hemophilia A patients by mutation screening and sequencing of FVIII gene. Using oligonucleotide site directed mutagenesis, we constructed FVIII mutants with missense mutations with- in the B-domain to study the effect of these mutations. To investigate the causality of such missense mutations expression studies were performed in Chinese hamster ovary cells (CHO), transfected with vector constructs encoding the FVIII protein variants (Fig. 2).

Results and Discussion

In the present study five mutated rFVIII-proteins Pro928Arg, Val993Leu, Asp1241Glu, Arg1310Gly and Asn1441Lys were expressed in CHO cells and charac- terized for FVIII activity (FVIII:C), FVIII antigen (FVIII:Ag)-level and the specific activity (FVIII:C[%]/FVIII:Ag[%]). The results were compared to the expression of wildtype FVIII protein. The protein variant Arg1241Glu has also been reported in the normal population thus representing a polymorphism. Four of the five mis- sense mutations (Pro928Arg, Val993Leu, Asp1241Glu, Arg1310Gly) showed signifi-

I. Scharrer/W. Schramm (Ed.)

34

th

Hemophilia Symposium Hamburg 2003

” Springer Medizin Verlag Heidelberg 2005

(2)

cantly expression of functional FVIII protein thus probably not being causative for a hemophilic phenotype. However, there were some differences in the specific activity and expression/secretion levels, which may point to a FVIII:C modulating effect. The Arg1310Gly variant showed secretion and specific activity (~1) very similar to nor- mal FVIII expression. The rFVIII-proteins Asp1241Glu and Pro928Arg exhibited a higher specific activity (~1,7-2), but secretion- and expression levels were only 50%

of the wild type protein. The rFVIII-protein Val993Leu showed nearly the same spe- cific activity (~0,9) as normal rFVIII, but slightly higher expression and secretion levels compared to wildtype FVIII. The expression studies of the Asn1441Lys variant gave inconclusive results and need further evaluation (Table 1).

Expression Studies of Recombinant FVIII Proteins Exhibiting Mutations 345

740 825 911 997 1083 1169 1255 1341 1427 1513 1599 1685

1685

782 868 954 1040 1126 1212 1298 1384 1470 1556 1642

928 993

1241

1310

1441

Fig. 1. Amino-acids of the B-Domain subjected to mutagenesis

Molecular Methods Methods Mutagenesis by PCR

Transformation Sequencing

Transfection

Selection Isolation

Stable Clone

Protein-Biochemnistry Cell Work

Fig. 2. Methods for the expression of

recombinant FVIII protein variants

(3)

346 K. Klempau et al.

Table 1. Characterization of recombinant FVIII protein variants

Sample AK tat. AK tat. AG tat. AG tat. AK/AG spec. AK Mass spec. AK/

cells mg/cells

[%] [U/ml] [%] [ng/ml] [U/mg] [mg] [U/mg*mg]

wt D2 0.75 0.0075 0.67 1.005 1.12 7.46 240 0.03

wt D2 0.74 0.0074 0.67 1.005 1.10 7.36 240 0.03

wt D2 1.08 0.0108 0.9 1.35 1.20 8.00 240 0.03

wt D2 1 0.01 0.9 1.35 1.11 7.41 240 0.03

wt D2 0.79 0.0079 0.9 1.35 0.88 5.85 240 0.02

wt D2 1.26 0.0126 0.9 1.35 1.40 9.33 240 0.04

wt D2 5.75 0.0575 5.17 7.755 1.11 7.41 240 0.03

wt D2 6.25 0.0625 5.78 8.67 1.08 7.21 240 0.03

wt E11 0.64 0.0064 0.43 0.645 1.19 9.92 190 0.05

wt E11 0.47 0.0047 0.43 0.645 1.09 7.29 190 0.04

wt E11 0.64 0.0064 0.67 1.005 0.96 6.37 190 0.03

wt E11 0.74 0.0074 0.67 1.005 1.10 7.36 190 0.04

wt E11 0.58 0.0058 0.43 0.645 1.35 8.99 190 0.05

wt E11 0.47 0.0047 0.43 0.645 1.09 7.29 190 0.04

wt E11 5.05 0.0505 5.11 7.665 0.99 6.59 190 0.03

wt E11 5 0.05 4.78 7.17 1.05 6.97 190 0.04

1241 F5 0.64 0.0064 0.43 0.645 1.49 9.92 90 0.11

1241 F5 0.74 0.0074 0.43 0.645 1.72 11.47 90 0.13

1241 F5 1.08 0.0108 0.67 1.005 1.61 10.75 90 0.12

1241 F5 1 0.01 0.67 1.005 1.49 9.95 90 0.11

1241 F5 0.69 0.0069 0.43 0.645 1.60 10.70 90 0.12

1241 F5 0.74 0.0074 0.43 0.645 1.72 11.47 90 0.13

1241 F5 2.74 0.0274 1.55 2.325 1.77 11.78 90 0.13

1241 F5 1.25 0.0125 1.22 1.83 1.02 6.83 90 0.08

1310 (G) E8 0.64 0.0064 0.67 1.005 0.96 6.37 280 0.02 1310 (G) E8 0.74 0.0074 0.67 1.005 1.10 7.36 280 0.03 1310 (G) E8 0.96 0.0098 1.14 1.71 0.86 5.73 280 0.02

1310 (G) E8 1 0.01 1.14 1.71 0.88 5.85 280 0.02

1310 (G) E8 0.69 0.0069 0.67 1.005 1.03 6.87 280 0.02 1310 (G) E8 0.74 0.0074 0.67 1.005 1.10 7.36 280 0.03 1310 (G) E8 5.86 0.0586 5.17 7.755 1.13 7.56 280 0.03

1310 (G) E8 6.5 0.065 5.56 8.34 1.17 7.79 280 0.03

928 E10 0.4 0.004 0.19 0.285 2.11 14.04 230 0.06

928 E10 0.47 0.0047 0.19 0.285 2.47 16.49 230 0.07

928 E10 0.98 0.0098 .043 0.645 2.28 15.19 230 0.07

928 E10 1 0.01 0.43 0.645 2.33 15.50 230 0.07

928 E10 0.58 0.0058 0.43 0.645 1.35 8.99 230 0.04

928 E10 0.74 0.0074 0.43 0.645 1.72 11.47 230 0.05

928 E10 3.99 0.0399 2.87 4.305 1.39 9.27 230 0.04

928 E10 3.75 0.0375 2.56 3.84 1.46 9.77 230 0.04

(4)

Conclusion

Expression studies represent a useful tool for studying the causality of missense mutations in the B-domain. The protein variants investigated in our study seemed not to be responsible for a hemophilic phenotype.

References

1. Klopp N, Oldenburg J, Uen C, Schneppenheim R, Graw J. 11 Hemophilia A patients without Mutations in the Factor VIII Encoding Gene. Thromb Haemost 2002; 88:357–60

2. Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, Moussalli MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsbury D. Mutations in the ER-Golgi intermediate com- partment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII.

Cell 1998; 93: 61–70

3. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352–6362 4. Pitmann DD, Kaufmann RJ. Site-directed mutagenesis and expression of coagulation factors

VIII and V in mammalian cells. Methods Enzymol 1993;222:236–260

Expression Studies of Recombinant FVIII Proteins Exhibiting Mutations 347

Table 1. Continue

Sample AK tat. AK tat. AG tat. AG tat. AK/AG spec. AK Mass spec. AK/

cells mg/cells

[%] [U/ml] [%] [ng/ml] [U/mg] [mg] [U/mg*mg]

993 F9 0.98 0.0098 1.14 1.71 0.86 5.73 170 0.03

993 F9 1 0.01 1.14 1.71 0.88 5.85 170 0.03

993 F9 1.19 0.0119 1.39 2.085 0.86 5.71 170 0.03

993 F9 1.26 0.0126 1.39 2.085 0.91 6.04 170 0.04

993 F9 0.92 0.0092 0.9 1.35 1.02 6.81 170 0.04

993 F9 1 0.01 0.9 1.35 1.11 7.41 170 0.04

993 F9 6.22 0.0622 6.16 9.24 1.01 6.73 170 0.04

993 F9 10 0.1 6.78 10.17 1.47 9.83 170 0.06

1441 F3 0.52 0.0052 0.19 0.285 2.74 18.25 120 0.15

1441 F3 0 0 0.19 0.285 0.00 0.00 120 0.00

1441 F3 0.98 0.0098 0.67 1.005 1.46 8.75 120 0.08

1441 F3 0.47 0.0047 0.67 1.005 0.70 4.68 120 0.04

1441 F3 0.46 0.0046 0.043 0.0645 10.70 71.32 120 0.59 1441 F3 0.21 0.0021 0.043 0.0645 4.88 32.56 120 0.27 1441 F3 1.14 0.0114 0.039 0.0585 29.23 194.87 120 1.62

1441 F3 0.5 0.005 0 0 0.00 0.00 120 0.00

Riferimenti

Documenti correlati

This book is an essential tool for understanding the problem of structural irregularities and provides the most up-to-date review on this topic, covering the aspects of

management of locally advanced pancreatic carcinoma: a qualitative systemic review. The argument for pre-operative chemoradiation for localized, radiographically resectable

Quest’ultimo conduceva gli allievi alla scoperta della ratio costruttiva dell’architettura del passato nelle sue lezioni di Storia e stili dell’architettura: “Delle

Government Printing Office , Social Security Administration (US)..

La seguente function riceve in input l’istante finale T, il passo di discretizzazione dt, la posizione iniziale i0, i parametri mu, delta e sigma, il numero M di simulazioni per

In 1998, a speci c algorithm was implemented in the Level 2 charged trigger (L2C) to select events compatible with decays into four charged particles, con- currently with the

3.6 Validation of the multilinear regression model with non-polar solvation, Lennard-Jones and electrostatic contributions scaled 95 3.7 Experimental and calculated folding free